ArticleImmunometabolism (Cobham, Surrey)2026
Modulatory effects of S1QEL on OxLDL-induced metabolic alterations and inflammatory responses in human monocytes.
Article in Immunometabolism (Cobham, Surrey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Background: Oxidized low-density lipoprotein (OxLDL) plays a key role in initiating monocyte activation, glycolytic reprogramming, and pro-inflammatory cytokine production-processes that contribute to aging and progression of age-related diseases such as atherosclerosis and steatohepatitis. Mitochondrial reactive oxygen species (ROS), particularly from complex I, are known modulators of these responses. This study aimed to evaluate the impact of OxLDL on the metabolic and inflammatory responses of primary human monocytes and determine whether co-treatment with site-1 Qo electron leak (S1QEL), a mitochondrial complex I-specific ROS suppressor, could mitigate these effects. Methods: Monocytes were isolated from healthy human donors and treated with OxLDL alone or in combination with S1QEL. Metabolic parameters including extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured using the Seahorse XF Analyzer. Pro-inflammatory gene expression (IL1B, CXCL8, IL6, TNF) was assessed using quantitative real-time polymerase chain reaction. Results: OxLDL treatment significantly increased ECAR, indicating enhanced glycolytic activity, without altering mitochondrial respiration (OCR). This metabolic shift was attenuated by S1QEL co-treatment. OxLDL also upregulated IL1B, CXCL8, and IL6 expression, which was significantly reduced by S1QEL. TNF expression remained unchanged across all conditions. Conclusions: S1QEL effectively suppresses both glycolytic reprogramming and pro-inflammatory cytokine expression induced by OxLDL in human monocytes. These findings underscore the role of mitochondrial complex I-derived ROS in monocyte activation and highlight S1QEL as a potential therapeutic agent for targeting inflammation in aging and several age-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.